Error message
Notice: Undefined index: content in _drupal_default_html_head() (line 345 of /var/www/vhosts/rovi.es/httpdocs/includes/common.inc).
|
Date |
Title |
Description |
PDF |
|
31 Jul 2024 |
On P&L |
The Company releases the first half 2024 financial results presentation
|
Download |
|
31 Jul 2024 |
On P&L |
The Company releases the press release related to the first half 2024 financial results
|
Download |
|
26 Jun 2024 |
On corporate transactions |
ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives
|
Download |
|
24 Jun 2024 |
On business and financial situation |
ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth
|
Download |
|
08 May 2024 |
On P&L |
The Company releases the press release related to the first three months of 2024 financial results
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
10 May 2023 |
Announcement of General Shareholders’ Meeting |
ROVI releases the information related to its General Shareholders Meeting
|
Download |
|
10 Apr 2023 |
Liquidity and counterparty agreements |
Liquidity contract: transactions conducted in the first quarter of 2023
|
Download |
|
21 Feb 2023 |
Annual Corporate Governance Report |
ROVI releases the 2022 Annual Corporate Governance Report
|
Download |
|
21 Feb 2023 |
Annual Report regarding remuneration of the members of the Board of Directors |
ROVI releases the 2022 annual report regarding remuneration of the members of the Board of Directors
|
Download |
|
16 Feb 2023 |
On business and financial situation |
The Company informs on the evaluation process to obtain marketing authorisation for Risvan® (Risperidone ISM®) in the United States.
|
Download |
Pages
|
Date |
Title |
Description |
PDF |
|
08 Oct 2018 |
Share capital increases and reductions |
Information on the registration in the Commercial Registry of Madrid of the notarial deed regarding the capital increase
|
Download |
|
05 Oct 2018 |
Buy-back programmes, stabilisation and treasury stock |
Information about the possibility that Jefferies International Limited carries out stabilisation transactions within the framework of the capital increase excluding pre-emptive subscription rights of the existing shareholders of Laboratorios Farmacéuticos Rovi, S.A.
|
Download |
|
04 Oct 2018 |
Share capital increases and reductions |
Directors’ Report and Independent Expert Report related to capital increase excluding preferential subscription rights
|
Download |
|
04 Oct 2018 |
Liquidity contracts and specialists |
The Company informs that has temporarily suspended liquidity agreement with JB Capital Markets, Sociedad de Valores, S.A.U.
|
Download |
|
04 Oct 2018 |
Share capital increases and reductions |
Information on price fixing and outcome of the private placement related to capital increase addressed to institutional investors, excluding preferential subscription rights
|
Download |
Pages
